Eieling Technology Limited (hereinafter referred to as ” Eieling Technology “) and Shanghai Jing’an District Central Hospital (hereinafter referred to as “Jing’an District Central Hospital”) officially signed a cooperation agreement to jointly build a “Liver Disease Health Promotion Demonstration Hospital”, marking a substantive step forward in the cooperation between the two parties, bringing unprecedented convenience, accuracy and accessibility to the field of chronic liver disease diagnosis.
The signing ceremony and industry-university-research exchange seminar were held yesterday at Jing’an District Central Hospital. The signing representatives were Professor Wang Hong (former vice president), Director of the Department of Gastroenterology of Jing’an District Central Hospital, Dr. Lin Yangmin, Project Director of Eieling Technology, Gu Erli, Director of the Department of General Medicine and Deputy Director of the Department of Gastroenterology of Jing’an District Central Hospital, and Professor Kelvin Wong, Director of the Knowledge Transfer and Entrepreneurship Office of the Hong Kong Polytechnic University, as witnesses.
As an affiliated hospital of Fudan University, Jing’an District Central Hospital has rich advantages in liver disease disciplines and an excellent medical team. It was approved as the first batch of regional medical centers in Shanghai, and is also the “National Fatty Liver Standard Diagnosis and Treatment Center” of the Chinese Medical Association’s Society of Hepatology. The hospital has a complete range of departments with distinctive characteristics, among which the Department of Gastroenterology is a key medical specialty in Shanghai. Under the leadership of Professor Yao Guangyi, a famous liver disease expert, the hospital has set an example for the prevention and treatment of liver diseases and played an important role in the prevention and treatment of the hepatitis A outbreak in Shanghai in 1988. Recently, the opening of a multidisciplinary outpatient clinic for fatty liver disease, led by the Department of Gastroenterology, has provided white-collar workers and people with “three highs” with a one-stop metabolic-related disease management service, and has also opened up the exploration of a new model of “white-collar building screening” health management.
As a company focusing on medical ultrasound solutions in the field of chronic liver disease, Eieling Technology has rich experience in scientific research and industrialization. The company’s founder and chief scientist, Professor Zheng Yongping, is the founding dean of the Department of Biomedical Engineering at the Hong Kong Polytechnic University, and has been selected as one of the top 2% of scientists in the world for three consecutive years. Eieling Technology was previously invited as a representative of Hong Kong’s innovation and technology companies to participate in the 8th “Belt and Road” Summit Forum co-organized by the Hong Kong Special Administrative Region Government and the Hong Kong Trade Development Council. As an important hub and key node for the high-quality joint construction of the “Belt and Road”, it will benefit countries along the route with innovative products. At the same time, Eieling Technology’s world-first patented product, the Liverscan® Mobile series of portable liver bomb analyzers, was unveiled at the 6th China International Import Expo in 2023 yesterday.
Integration into the overall national development has a wide scope and unlimited opportunities. This round of cooperation between the two sides is not only a microcosm of the linkage between Hong Kong and Shanghai but also based on the national strategies such as the “14th Five-Year Plan” and the joint construction of the “Belt and Road” high-quality development. Each side will give full play to its inherent and emerging advantages, expand all possible opportunities to the maximum, and maximize all possible values.
It is worth mentioning that this is not the first time that Hong Kong and Shanghai have worked together. As early as 2008, some liver disease and infection experts from the mainland and Hong Kong held a special seminar in Shanghai on how to further improve the efficacy of lamivudine in the treatment of chronic hepatitis B, and prevent and reduce drug resistance. The experts at the meeting conducted in-depth discussions based on relevant research results and clinical practice experience and formed opinions on how to optimize the treatment plan of lamivudine. After modification and review by some experts, it was submitted to the expert meeting convened by Professor Yao Guangyi and Professor Weng Xinhua on January 15, 2009, for centralized review.
Looking ahead, Eieling Technology and Jing’an District Central Hospital will continue to strengthen cooperation and work together to build a “liver disease health promotion demonstration hospital”. Through the popularization of high-end technology and the extension of grassroots services, the two parties will provide more liver disease patients with convenient and accurate diagnostic services, and strive to explore alternatives to traumatic indicators to help improve patients’ quality of life and health level. At the same time, this cooperation will also set an example for innovation and development in the medical industry, and promote cooperation and exchanges in the field of medical health between Hong Kong and Shanghai to a higher level.